Edward B. Garon, MD | Authors

Edward B. Garon, MD, Discusses Outcomes in NSCLC With Dato-DXd From TROPION-PanTumor01

October 14, 2021

CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.

Management of Small-Cell Lung Cancer: Time to Move Forward

October 15, 2010

Small-cell lung cancer (SCLC) is a pathologically distinct malignancy of the lung, characterized by rapid growth, propensity for early metastatic spread, and responsiveness to chemotherapy and radiation. Despite its generally good initial response, the relapse and subsequent mortality rate remain very high. Only 3% to 8% of all patients survive 5 years, and median survival for extensive stage disease is 8 to 13 months.[1,2]